Caribou Biosciences (NASDAQ:CRBU – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Insider & Institutional Ownership
77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Caribou Biosciences has a beta of 2.5, indicating that its stock price is 150% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Caribou Biosciences and CRISPR Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Caribou Biosciences | 1 | 4 | 1 | 1 | 2.29 |
| CRISPR Therapeutics | 1 | 8 | 8 | 2 | 2.58 |
Caribou Biosciences presently has a consensus price target of $4.50, suggesting a potential upside of 902.90%. CRISPR Therapeutics has a consensus price target of $69.69, suggesting a potential upside of 39.18%. Given Caribou Biosciences’ higher probable upside, equities research analysts plainly believe Caribou Biosciences is more favorable than CRISPR Therapeutics.
Profitability
This table compares Caribou Biosciences and CRISPR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Caribou Biosciences | -1,085.00% | -95.38% | -65.81% |
| CRISPR Therapeutics | -1,812.07% | -25.59% | -17.89% |
Valuation & Earnings
This table compares Caribou Biosciences and CRISPR Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Caribou Biosciences | $11.16 million | 4.31 | -$148.12 million | ($1.08) | -0.42 |
| CRISPR Therapeutics | $23.32 million | 208.24 | -$581.60 million | ($4.74) | -10.56 |
Caribou Biosciences has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Caribou Biosciences beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
